Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic

Chiranjib Chakraborty 1,2,*, Ashish Ranjan Sharma 2,†, Manojit Bhattacharya 3,†, Garima Sharma 4, Rudra P. Saha 1, Sang-Soo Lee 2,*

1Department of Biotechnology, School of Life Science & Biotechnology, Adamas University, Kolkata 700126, India
2Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon 24252, Korea
3Department of Zoology, Fakir Mohan University, Balasore 756020, India
4Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Chuncheon, Korea

ABSTRACT

Coronavirus disease 2019 (COVID-19) has developed as a pandemic, and it created an outrageous effect on the current healthcare and economic system throughout the globe. To date, there is no appropriate therapeutics or vaccines against the disease. The entire human race is eagerly waiting for the development of new therapeutics or vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Efforts are being taken to develop vaccines at a rapid rate for fighting against the ongoing pandemic situation. Amongst the various vaccines under consideration, some are either in the preclinical stage or in the clinical stages of development (phase-I, -II, and -III). Even, phase-III trials are being conducted for some repurposed vaccines like Bacillus Calmette–Guérin, polio vaccine, and measles-mumps-rubella. We have highlighted the ongoing clinical trial landscape of the COVID-19 as well as repurposed vaccines. An insight into the current status of the available antigenic epitopes for SARS-CoV-2 and different types of vaccine platforms of COVID-19 vaccines has been discussed. These vaccines are highlighted throughout the world by different news agencies. Moreover, ongoing clinical trials for repurposed vaccines for COVID-19 and critical factors associated with the development of COVID-19 vaccines have also been described.

Keywords: Vaccines; Clinical trial; COVID-19; Repurposed vaccines; SARS-CoV-2

INTRODUCTION

Coronavirus disease 2019 (COVID-19) has developed as a pandemic in no time and has challenged and also burdened the world’s entire health care system. The mortality rate of COVID-19 has been predicted to be around 3%–4% (1). It has been observed that the risk of COVID-19 mortality is higher in the aged population and those having comorbidities (2-4). The current burden for the disease is estimated to be more than 1 trillion US$ in the world economy and is continually rising with each passing day (5). Therefore, there is an urgent and unusual health challenge for the entire human race. Presently, there is no suitable therapeutic or vaccine available to counter this disease. A successful vaccine can help to reduce infection as well as it can significantly diminish the morbidity and mortality of this killer disease. Conversely, an effective vaccination regime for the population will help restrain the economic burden of a country.
It is well accepted that the vaccination is the most effective and significant therapeutic approach to prevent and control any infectious diseases (6). However, in general, it has been noted that several years are required to develop a new vaccine. For instance, 5 years have been taken for the development of the Ebola vaccine. Nevertheless, till date there is no vaccine against severe acute respiratory syndrome coronavirus (SARS-CoV-1) or Middle East respiratory syndrome-related coronavirus (MERS-CoV) (6). From the previous experience in the past decade, we have understood that the researchers and the vaccine industry should act immediately in an integrated manner to develop new vaccines to fight against any epidemic or pandemic situation. However, in most cases like the development of Zika, H1N1 influenza, Ebola, etc., vaccines took a long time to address the urgency of treatment or containment.

We are required to develop the vaccine on an exigent basis to encounter sudden arising epidemic or pandemic situations. One such exceptional case is the H1N1 influenza vaccine, which was developed more quickly than other vaccines (7). Now in the current COVID-19 pandemic situation, scientists and biotechnological companies have been asked to develop the vaccines rapidly to combat the spread of COVID-19.

In this extensive review, we have tried to update the current information available for the antigenic epitopes for the SARS-CoV-2 vaccine development and the various types of platforms utilized for COVID-19 vaccine development like an inactivated vaccine, live-attenuated vaccine or whole virus vaccines, nucleic acid vaccines, subunit vaccines, and recombinant vaccines. Further, an illustration of the clinical trial landscape for COVID-19 vaccine development as well as for the repurposed vaccines has been provided. Moreover, in this article, we have comprehensively discussed some noteworthy vaccine candidates and their developers, such as mRNA-1273 from ModernaTX. Inc, adenovirus type-5 (Ad5)-nCoV from CanSino Biologics Inc., INO-4800 from Inovio Pharmaceuticals, LV-SMENP-DC from Shenzhen Geno-Immune Medical Institute, artificial Ag-presenting cells (aAPC) from Shenzhen Geno-Immune Medical Institute, LUNAR-COV19 from Arcturus Therapeutics, Adjuvanted Protein Vaccine from GlaxoSmithKline (GSK) and Sanofi, mRNA Vaccine (BNT162) from BioNTech SE, Synthetic mRNA Vaccine from Curevac, COVAX19 from Vaxine, AdVac and PER.C6 technology-based vaccine from Johnson & Johnson. Finally, we have discussed some factors that are associated with the COVID-19 vaccine designing and development, such as the timeline of COVID-19 vaccine development, strategic collaboration for this vaccine development, and the scale-up probabilities.

VACCINE AND COVID-19

There is an urgent need for the COVID-19 vaccine to fight against the pandemic in the current situation. The entire world is eagerly waiting for the vaccine to be available in the market. Every section of the human population is being affected drastically. Moreover, a financial burden has been imposed due to the current crisis in every nation of this world.

A vaccine is designed and developed to boost the natural immune response against invading pathogens, especially viruses. In fact, vaccination produces long-lasting immunity to individuals exposed to inactivated Ags (8). It also helps to develop immunological memory to combat against the live pathogens. It can function either by providing immunity through the humoral Ab production or trigger the cellular T cells to mediate acquired immunity.
Scientists and the biotech industry are trying to develop the COVID-19 vaccine at a very astonishing speed to diminish the pandemic situation. Scientists have entitled this speedy vaccine development process as “vaccine development through pandemic speed” (7,9). Various past researches have contributed effectively to the rapid progress of the development of the COVID-19 vaccine. For instance, previous studies and diverse knowledge on the characteristic features of various coronavirus spike (S) proteins and its role in pathogenesis (specially SARS-CoV-1 spike protein), the antigenicity of the virus glycoprotein, and the knowledge about immunity and neutralizing Ab to spike proteins contributed immensely to the cause of COVID-19 vaccine (10,11). The previous knowledge about the nucleic acid vaccine technology also helped in the prompt manufacture of the mRNA vaccine against SARS-CoV-2 (12,13).

However, it is essential to understand the target population for immediate vaccination. On priority, the target population for vaccination includes school children, frontline healthcare workers, people with more than 60 years of age, and people with comorbidities including hypertension, diabetes, cardiovascular diseases, and renal disease (14,15).

ANTIGENIC EPITOPES AND COVID-19 VACCINE DEVELOPMENT

Previously, it has been reported that the SARS-CoV recovered patients have specific Abs against SARS-CoV. In this case, human Abs were directed primarily to the SARS-CoV S glycoprotein and its receptor-binding domain (RBD). SARS-CoV requires RBD to bind to the angiotensin-converting enzyme 2 (ACE2) for entering into the host cell (16). Similarly, for SARS-CoV-2 vaccine development, researchers are analyzing whether the S glycoprotein and its RBD show a similar type of function or not (17). However, some potential epitopes might be present in the S protein other than in RBD alone. Hence, apart from epitopes present in RBD, other S proteins’ epitopic sequences should be considered for developing effective vaccine candidates (17,18).

To determine conserved epitopes is a proposed strategy for vaccine development (19). A similar approach is being applied against SARS-CoV-2 as well (20,21). It has been observed that only 77% of the amino acid sequence are in the similarity between the S protein of SARS-CoV and SARS-CoV-2. Therefore, a significant variation might be expected in the RBD of these two viruses (22,23). Moreover, it has been reported that several Abs against the S protein of SARS-CoV-2 are not showing a similar type of binding and neutralizing capacity as SARS-CoV (24-26). However, using epitopes in the S1B RBD core domain of SARS-CoV-2, Abs have been identified (23,24,27). They might be a promising vaccine candidate for the pandemic virus. However, developing a muti-epitopic viable vaccine utilizing various proteins such as N-protein, S-protein, and M-protein against this virus is still an unfinished task (28).

PROTECTIVE IMMUNITY AGAINST SARS-CoV-2 INFECTIONS

Scientists are trying to understand the protective immunity against SARS-CoV-2 infections. It is currently a significant challenge to how protective immunity against this virus can be generated (29,30). COVID-19 infection ranges from silent infection to lethal disease and largely depends on the inter-individual clinical variability. There may be a role of human
genetics in determining the inter-individual clinical variability and protective immunity against this virus (31). It has been observed that successful vaccines have a protective role against this virus (32). However, the selection of Ags is crucial for effective vaccine development and protective immunity against this virus. One such recent example is the COVID-19 vaccine candidate developed by Yang et al. (33). The vaccine candidate shows a protective immunity against SARS-CoV-2 and uses RBD of the S-protein as an Ag. The researchers have noted that CD4 T lymphocytes and quite a few immune pathways are involved in initiating the vaccine Ab response (33). Similarly, several vaccine candidates are in the developmental stages, showing a high titer of neutralizing Abs (nAbs) induced by the vaccines. However, it is presumed that the safe and effective vaccine candidates will create protective immunity against the virus and fight against the pandemic situation.

DIFFERENT TYPES OF VACCINES PLATFORM OF COVID-19 VACCINES

Various types of vaccine platforms have been used for vaccine development from time to time. Vaccines traditionally licensed for human beings are either lively-attenuated virus (majority) or protein-conjugated subunits or virus-like particulate substances, polysaccharides, or inactivated viruses. During the last decade, advanced technological platforms have been introduced for vaccine development, such as nucleic acid vaccine (DNA or RNA vaccine) and the recombinant viral vaccine. Supplementary Table 1 summarizes the major vaccine platforms which are under consideration for the development of the COVID-19 vaccine.

Inactivated vaccine
This type of vaccine consists of pathogens that are inactivated for pathogenicity. These pathogens are usually grown in culture and are inactivated by various means. The inactivated virus vaccine has been in use for a long time. An example of such a vaccine is the inactivated polio vaccine (34). Gao et al. (35) recently developed a purified inactivated vaccine candidate for the SARS-CoV-2 virus. The name of the inactivated vaccine candidate is PiCoVacc and was shown to possess the ability to generate neutralizing Abs against this deadly virus in rats, mice, as well as in primates other than humans. It was reported that the vaccine generated Abs were able to neutralize 10 different strains of SARS-CoV-2. Researchers have analyzed two different doses for vaccination for protection: 3 μg and 6 μg per dose. The lower dose (3 μg) provided partial protection, while the higher dose (6 μg) gave complete protection. Presently, this inactivated vaccine (PiCoVacc) is under clinical trial (35,36). However, the vaccine requires a booster dose to maintain stable immunity, which is a disadvantage of this vaccine. For this case, a large quantity of virus needs to be handled, making another disadvantage of the vaccine.

Live-attenuated vaccine or whole virus vaccines
The live-attenuated vaccine is another type of vaccine that has been in use for a long time. The typical example of a live-attenuated vaccine is measles-mumps-rubella (MMR) vaccine (37). Recently, Grenga et al. (38) tried to develop a whole virus vaccine against SARS-CoV-2 and tried to characterize the host cell protein dynamics through proteomics.

It was reported that scientists in Hong Kong developed a live influenza vaccine. This vaccine also expressed the proteins of SARS-CoV-2 (15). However, live attenuated virus vaccines or whole virus vaccines require extensive additional safety and need strict efficacy trials (39). It is the drawback of this vaccine.
**Subunit vaccines**

Subunit vaccine contains the antigenic fragments of a pathogen, especially the surface protein, and can elicit the immune response against the pathogen (40). One such example is the influenza subunit vaccine, a thermo-stable and freeze-dried vaccine (41).

Several scientists are trying to develop the subunit vaccine for SARS-CoV-2. Kalita et al. (42) has attempted to design a subunit vaccine for COVID-19. Researchers are trying to target the S1 subunit of this virus to produce Abs (43). Another subunit vaccine developed by Qi et al. (44) comprises a recombinant fusion protein of the RBD subunit of SARS-CoV-2 and mouse IgG1 Fc domain. They reported that the subunit vaccine produced potent neutralizing Abs and stimulated cellular and humoral immunity in mice (44). Recently, a subunit vaccine was developed by Clover Biopharmaceuticals, containing a trimerized S protein. The company has used patented Trimer-Tag® technology for this subunit vaccine production (15). However, it has been noted that subunit vaccines require multiple booster shots to boost complete immunity from the pathogens (43), and it is one of the disadvantages of this vaccine. In this case, memory for future immune response is highly undoubtful.

**Nucleic acid vaccines**

The nucleic acid vaccine can be regarded as a modern era vaccine. The vaccine has several advantages over other types of vaccines. Firstly, this vaccine can be quickly constructed. Secondly, it can induce strong cell-mediated and humoral immune responses, even in the absence of an adjuvant (45,46).

**DNA vaccines**

Recently, DNA vaccines are being developed against SARS-CoV-2 virus by different research groups. The developed DNA vaccines mainly encode different S proteins of the SARS-CoV-2 virus. This DNA vaccine has been shown to stimulate both cellular and humoral immune responses in different animals, such as guinea pigs, mice, and rhesus macaques (47,48). Recently, a synthetic DNA-based vaccine candidate was developed for targeting SARS-CoV-2 S protein (INO-4800) (49). Similarly, another DNA vaccine showed protection against this virus in nonhuman primate animal model. The vaccine elicited the production of nAbs and generated protective immunity (48). The limitation of this vaccine is that it elicits both humoral as well as cytotoxic immunity. Therefore, titers sometimes remain low. It may induce Ab production against itself, which is another disadvantage of this vaccine (50).

**RNA vaccines**

Similarly, RNA vaccines are also being developed for this killer virus (12,51). It has been noted that the RNA is generally delivered via lipid nanoparticles (LNPs). Some mRNA vaccines that are being developed against this virus have shown high potency. These are promising vaccine candidates compared to conventional vaccines. The mRNA-1273 appears to be a promising vaccine candidate against this virus in nonhuman primates and have showed induced Ab production levels (52). This vaccine candidate shows safety and immunogenicity, even in older populations (53). Another mRNA vaccine candidate is BNT162b1, which is a lipid-nanoparticle formulated vaccine. It showed safety and tolerability among 18–55 years healthy adults in phase-I/II clinical trial (54). However, the technology of mRNA vaccine is new; however, one of this technology’s advantages is that the vaccine is produced absolutely in vitro method (55). Unfortunately, this vaccine candidate is very unstable, making it a non-significant vaccine candidate.
Recombinant vaccines

Scientists use the recombinant vaccine platform to avoid the need to work with live infectious viruses. In this case, adjuvants can be applied to increase immunogenicity (51). A recombinant MERS-CoV vaccine was developed by expressing the S protein of MERS-CoV. It has been successfully evaluated through the phase-I trial (56). Lei et al. (57) have made an attempt to develop a recombinant vaccine using ACE2-Ig against the SARS-CoV-2 virus. Kim et al. (58) have developed another recombinant vaccine by utilizing the SARS-CoV-2 S1 subunit sequence. Interestingly, this vaccine can be delivered through microneedle arrays technology to develop IgG Abs (59). However, there are some limitations to recombinant vaccines. It uses a subunit sequence that may not induce the proper Ab production. Therefore, effective Ag and adjuvant selection are essential for this type of vaccine development (60).

Peptide and protein vaccine

Peptide vaccines are synthetic vaccines composed of a chemically synthesized chain of 20-30 amino acids of specific antigenic B cells and/or T cells epitope (20,21). These peptides are associated with the infectious virus and are able to induce specific immune responses. The advantages of peptide and protein vaccines are low cost, easy synthesis, increased relative safety, and stability (61). Various peptide vaccine candidates are currently studied and are in different stages of vaccine development. In this case, the selection of Ags, delivery system, and adjuvants is a critical process. Selection decides the efficacy of the vaccine as well as the inducibility of immune response. Moreover, the safety of the delivery strategy is another significant concern (62).

Virus-like particles (VLPs)

VLPs are self-assembled structures composed of the viral envelope and/or capsid proteins. In most cases, these VLPs represent a similar structure and antigenicity as the parent virus. In addition, VLPs can serve as platforms for the possible modification, i.e., insertion or fusion of foreign proteins, via chemical conjugation to develop chimerically VLPs. VLPs possess more potent immunogenic properties than recombinant or subunit vaccines (61,63). Therefore, VLPs are recognized as the best suitable candidate for vaccine development. However, in case of VLPs, highly efficient delivery vehicles selection is a critical process and it is one of the disadvantages of this vaccine (64).

PRECLINICAL STUDIES FOR COVID-19 VACCINE DEVELOPMENT

According to World Health Organization, various vaccine candidates for COVID-19 are currently in preclinical development (65). Some of the vaccine candidates for COVID-19 that are in preclinical stages are shown in Supplementary Table 2. In a vaccine developmental process, preclinical testing in animals is one of the prerequisites for the approval of any vaccine candidate before clinical trials. It has been observed that most of the suggested vaccine or therapeutic candidates fail to confirm their efficacy in animals (66), though they show efficacy in vitro conditions. It might be due to the simplified and outdated in vitro conditions that are unable to mimic the complex in vivo environment.

Presently, it is essential to enhance the speed of studies owing to the faster spread of COVID-19. Therefore, there is an urgent need to update preclinical studies’ standards to
ensure the efficacy and safety of vaccine candidates before entering clinical trials for human use. Recently, various bioengineering tools have been developed to speed up the vaccine development process for COVID-19, such as 3-dimensional (3D) culture models, microfluidic chambers, and intravital imaging (67). The 3D and organoid models can represent in vivo-like dynamics, compared to 2D cell monoculture models. Moreover, organoids and 3D models are more permissive for viral infections and show more realistic expression markers to confirm the maximum extent of vaccine efficacy.

**CLINICAL TRIAL LANDSCAPE FOR COVID-19 VACCINE DEVELOPMENT**

Currently, more than 135 vaccines are being developed for COVID-19. Several vaccines are in their preclinical trial stages, while few of them have entered the different phases of clinical trials (46). International Committee entitled “International Committee of Medical Journal Editors” has advocated in 2005 that all clinical trials can be registered in the public domain and can be considered for publication (59). The relevant publicly available domains are ClinicalTrials.gov, European clinical registry, and the International Clinical Trials Registry Platform. These domains can be accessed for different facts and figures of the clinical trials, such as patient group, methodology, inference, and the outcome of the clinical trial (Fig. 1A).

To date, more than 64 novel vaccines have been registered and are in various development stages of clinical trials. Near about 28 registries have been documented for phase-I clinical trials (Table 1). About 23 registries have been noted for the phase-II clinical trial (Table 2), and about 5 registries were reported for the phase-III clinical trial (Table 3).

Moderna developed an mRNA encapsulated LNPs based vaccine, and this was a collaborative effort of the company with the Research Center at NIH. Currently, it is in phase-I clinical trial (NCT04283461, ClinicalTrials.gov). It was the first vaccine to begin clinical trials outside of China and was highlighted in the news (68).

Figure 1. Different information about SARS-CoV-2 vaccine development and clinical trial. (A) Flow diagram that describes the clinical selection process of different vaccines during our study, which is in different phases of the clinical trial. (B) Different clinical trial phases of vaccine deployment and their salient features.
### Table 1. Ongoing/completed phase-I clinical trial for COVID-19 vaccines

| Sl. No. | Clinical trial ID | Study start date and end date (probable) | No. of patients enrolled in this clinical trial | Randomized | Developer | Country of origin | Vaccine type | Current status | Remark |
|---------|-------------------|------------------------------------------|-----------------------------------------------|------------|-----------|-------------------|--------------|---------------|--------|
| 1       | NCT04283461       | March 16, 2020 and November 22, 2021     | 120                                            | No         | National Institute of Allergy and Infectious Diseases | United States | mRNA         | Not recruiting | Study understand the immunogenicity and safety of mRNA-1273 vaccine |
| 2       | NCT04299724       | February 15, 2020 and December 31, 2024   | 100                                            | No         | Shenzhen Geno-Immune Medical Institute               | China         | Artificial antigen presenting cells | Recruiting | Study uses aAPC vaccine for 100 human which received subcutaneous injection to understand immunogenicity |
| 3       | NCT04428073       | July 2020 and December 2021              | 32                                             | No         | GeneCure Biotechnologies                             | USA           | Therapeutic vaccine (Covax-19™) | Not yet recruiting | Measuring the severity of local and systemic adverse events |
| 4       | NCT03349670       | July 20, 2020 and November 10, 2020      | 20                                             | No         | Medicine Invention Design, Inc.                     | USA           | Multiple gene mutation COVID-19 virus strains | Not recruiting | Assess for therapeutic vaccine activity and suggests the potential benefit of this vaccine |
| 5       | NCT04313127       | March 16, 2020 and December 20, 2022     | 108                                            | No         | CanSino Biologics Inc.                              | China         | Ad5 vector (Ad5-nCoV) | Not recruiting | This recombinant vaccine (Ad5-nCoV) understands safety and immunogenicity |
| 6       | NCT04405908       | June 19, 2020 and March 30, 2021         | 150                                            | Yes        | Clover Biopharmaceuticals AUS Pty Ltd               | Australia     | Subunit type vaccine of recombinant trimeric S protein | Recruiting | Alum adjuvant linked multiple dosage level study |
| 7       | NCT04450004       | July 10, 2020 and April 30, 2021         | 180                                            | Yes        | Medicago Inc.                                       | Canada        | Recombinant coronavirus-like particle (VLP) | Recruiting | Assessment the safety and immunogenicity using this vaccine containing VLP |
| 8       | NCT04453852       | June 30, 2020 and July 1, 2021           | 40                                             | Yes        | Vaxine Pty Ltd                                      | Australia     | Monovalent recombinant S protein vaccine | Recruiting | To understand the safety and immunogenicity of this recombinant vaccine |
| 9       | NCT04449276       | June 18, 2020 and August 2021            | 168                                            | Yes        | CureVac AG                                          | Germany       | mRNA vaccine          | Recruiting | Evaluate the safety and reactogenicity of mRNA based vaccine (CvnCoV) through IM injection |
| 10      | NCT04336410       | April 3, 2020 and July 2021              | 120                                            | No         | Inovio Pharmaceuticals                               | United States | DNA vaccine (INO-4800) | Not recruiting | INO-4800 vaccine was used to evaluate the safety, tolerability and immunogenicity |
| 11      | NCT04276896       | March 24, 2020 and December 31, 2024     | 100                                            | No         | Shenzhen Geno-Immune Medical Institute               | China         | Protein vaccine       | Recruiting | This protein vaccine modulate T cell response |
| 12      | ChiCTR2000030906   | March 16, 2020 and December 31, 2020     | 36                                             | No         | Jiangsu Provincial Center for Disease Control and Prevention | China         | mRNA                  | Recruiting | Recombinant type adenoviral vector based vaccine targeted to COVID-19 |
| 13      | NCT04324606       | April 23, 2020 and October 2021          | 1,090                                          | Yes        | University of Oxford                                 | United Kingdom| Adenovirus-vectored vaccine (COV001) | Not recruiting | This vaccine (COV001) was used among contain 1090 volunteers to understand the immunogenicity |
| 14      | NCT04470609       | July 10, 2020 and November 2021          | 471                                            | Yes        | Chinese Academy of Medical Sciences                 | China         | Inactivated type of vaccine | Enrolling by invitation | This trial evaluate the immunogenicity and doses |
| 15      | NCT04412538       | May 15, 2020 and September 2021          | 942                                            | Yes        | Chinese Academy of Medical Sciences                 | China         | Inactivated type of vaccine | Recruiting | In this study healthy volunteers (18 to 59 years) was chosen to understand the immunogenicity |
| 16      | NCT04276896       | March 24, 2020 and December 31, 2024     | 100                                            | No         | Shenzhen Geno-Immune Medical Institute               | China         | Synthetic Minigene vaccine | Recruiting | This vaccine contains viral structural proteins etc. |
The significant vaccines registered for phase-I clinical trials are assessed for safety, dosage, and immunogenicity. In this stage, the vaccine is applied to 80 to 100 healthy human subjects. Some dominant vaccine candidates that are in phase-I clinical trial are artificial Ag-presenting cells or aAPC based vaccine (NCT04299724), adenoviral vector 5 based vaccine (NCT04313127), mRNA based vaccine (NCT04283461), DNA based vaccine (NCT04336410), chimpanzee adenoviral vector ChAdOx1 based vaccine (NCT04324606), and a lentiviral vector-based vaccine (NCT04276896) (69) (Table 1).

The vaccines that are registered for the phase-II clinical trials are assessed for the effectiveness and associated side effects if any. In this stage, the vaccine is applied to 100 to

---

**Table 1. (Continued) Ongoing/completed phase-I clinical trial for COVID-19 vaccines**

| Sl. No. | Clinical trial ID | Study start date and end date (probable) | No. of patients enrolled in this clinical trial | Randomized | Developer | Country of origin | Vaccine type | Current status | Remark |
|--------|-------------------|------------------------------------------|-----------------------------------------------|------------|-----------|------------------|--------------|---------------|--------|
| 17     | NCT04473690       | December 20, 2020 and March 23, 2024     | 180                                            | Yes        | Kentucky BioProcessing, Inc. | United States | KBP vaccine   | Not yet recruiting | Adult subjects of different age group was accessed and evaluated immunogenicity and safety |
| 18     | NCT04445389       | June 17, 2020 and June 17, 2022          | 210                                            | Yes        | Genexine, Inc.          | Korea, Republic of | DNA vaccine  | Recruiting     | This DNA vaccine was used to understand the immunogenicity and tolerability among 60 healthy volunteers |
| 19     | NCT04380532       | May 15, 2020 and June 15, 2021           | 20                                             | No         | Immunitor LLC          | Canada         | Tableted thermostable vaccine | Not recruiting | Tableted vaccine developed from pooled plasma of COVID-19 patients |
| 20     | NCT04386252       | February 2021 and February 2022          | 175                                            | Yes        | Aivita Biomedical, Inc. | United States | DC vaccine    | Not yet recruiting | Antigens combined with autologous DCs is the combination of this vaccine |
| 21     | NCT04334980       | October 2020 and February 28, 2021       | 12                                             | Yes        | Symvivo Corporation United States | United States | bacTRL-spike vaccine | Not yet recruiting | This is orally delivered vaccine |
| 22     | NCT04398147       | August 1, 2020 and December 30, 2021     | 696                                            | Yes        | CanSino Biologics Inc.  | Canada         | Recombinant nCoV (Ad5 vector) vaccine | Not yet recruiting | To understand the safety, tolerability of Ad5-nCoV |
| 23     | NCT04471519       | July 13, 2020 and June 30, 2021          | 755                                            | Yes        | Bharat Biotech International Limited | India         | Whole-Virion inactivated type vaccine | Recruiting | BBV152 vaccine formulations was access in 3 investigational subgroups |
| 24     | NCT04463472       | June 29, 2020 and July 31, 2021          | 30                                             | No         | AnGes, Inc.            | Japan          | DNA vaccine       | Recruiting | Study to assess safety and immunogenicity of 2 doses of IM AG0301-COVID-19 |
| 25     | NCT04444674       | June 24, 2020 and December 2021          | 2,130                                          | Yes        | University of Witwatersrand | South Africa  | ChAdOx1 nCoV-19 vaccine | Recruiting | This study accessed the immunogenicity and safety of adult aged 18-65 years living with and without HIV |
| 26     | NCT04380701       | April 23, 2020 and November 2020         | 456                                            | No         | BioNTech RNA Pharmaceuticals GmbH | Germany      | RNA vaccine        | Recruiting | This RNA vaccine evaluate the immunogenicity and safety |
| 27     | NCT04480957       | August 4, 2020 and January 2021          | 92                                             | Yes        | Arcturus Therapeutics, Inc. | Singapore         | Self-replicating (replicon) mRNA formulated in a LNP | Not yet recruiting | Safety and tolerability and immunogenicity of investigational vaccine ARCT-021 |

Information has been taken from: https://ClinicalTrials.gov, EU Clinical Trials Register, Chinese Clinical Trial Register. All information about the table was accessed on 30 November 2020.
# Ongoing Clinical Trials of COVID-19 Vaccines

## Table 2. Ongoing/completed phase-II clinical trial for COVID-19 vaccines

| Sl. No. | Clinical trial ID | Study start date and end date (probable) | No. of patients enrolled in this clinical trial | Randomized | Developer | Country of origin | Vaccine type | Current status | Remark |
|---------|-------------------|------------------------------------------|-----------------------------------------------|------------|-----------|-------------------|--------------|---------------|--------|
| 1       | NCT04405076       | May 29, 2020 and August 2021             | 600                                           | Yes        | ModernaTX, Inc | United States     | mRNA         | Not recruiting | Study was performed for dose-confirmation and accessed the safety. |
| 2       | NCT04470609       | July 10, 2020 and November 2021          | 471                                           | Yes        | Chinese Academy of Medical Sciences | China         | Inactivated type of vaccine | Enrolling by invitation | This trial evaluate the immunogenicity and doses |
| 3       | NCT04412538       | May 15, 2020 and September 2021          | 942                                           | Yes        | Chinese Academy of Medical Sciences | China         | Inactivated type of vaccine | Recruiting | In this study healthy volunteers (18 to 59 years) was chosen to understand the immunogenicity. |
| 4       | NCT04276896       | March 24, 2020 and December 31, 2024     | 100                                           | No         | Shenzhen Geno-Immune Medical Institute | China         | Synthetic Minigene vaccine | Recruiting | This vaccine contains viral structural proteins etc. |
| 5       | NCT04437875       | June 17, 2020 and August 10, 2020        | 38                                            | No         | Gamaleya Research Institute of Epidemiology and Microbiology | Russian Federation | Lyophilisate solution | Completed | Gam-COVID-vaccine lyophilisate to open study of safety, tolerability and immunogenicity |
| 6       | NCT04473690       | December 20, 2020 and March 23, 2024     | 180                                           | Yes        | Kentucky BioProcessing, Inc. | United States | KBP vaccine | Not yet recruiting | Adult subjects of different age group was accessed and evaluated immunogenicity and safety. |
| 7       | NCT04445389       | June 17, 2020 and June 17, 2022          | 210                                           | Yes        | Genexine, Inc. | Korea, Republic of | DNA vaccine | Recruiting | This DNA vaccine was used to understand the immunogenicity and tolerability among 150 healthy volunteers. |
| 8       | NCT04380532       | May 15, 2020 and June 15, 2021           | 20                                            | No         | Immunitor LLC | Canada         | Tableted thermostable vaccine | Not recruiting | Tableted vaccine developed from pooled plasma of COVID-19 patients. |
| 9       | NCT04341389       | April 12, 2020 and January 31, 2022      | 508                                           | Yes        | Institute of Biotechnology, Academy of Military Medical Sciences | China         | Ads vector (Ad5-nCoV) | Not recruiting | In this study Ads-nCoV was accessed among 508 healthy volunteers. |
| 10      | NCT04386252       | February 2021 and February 2022          | 175                                           | Yes        | Alvita Biomedical, Inc. | United States | DC vaccine | Not yet recruiting | Antigens combined with autologous DCs is the combination of this vaccine. |
| 11      | NCT04324606       | April 23, 2020 and October 2022          | 1,090                                         | Yes        | University of Oxford | United Kingdom | ChAdOx1 nCoV-19 | Not recruiting | This study accessed the immunogenicity and safety. |
| 12      | NCT04398147       | August 1, 2020 and December 30, 2021     | 696                                           | Yes        | CanSino Biologics Inc. | Canada         | Recombinant nCoV (Ad5 vector) vaccine | Not yet recruiting | To understand the safety, tolerability of Ad5-nCoV. |
| 13      | NCT04471519       | July 13, 2020 and June 30, 2021          | 755                                           | Yes        | Bharat Biotech International Limited | India | Whole-Virion inactivated type vaccine | Recruiting | BBV152 vaccine formulations was access in 3 investigational subgroups. |
| 14      | NCT04463472       | June 29, 2020 and July 31, 2021          | 30                                            | No         | AnGes, Inc. | Japan          | DNA vaccine | Recruiting | Study to assess safety and immunogenicity of 2 doses of IM AG0301-COVID-19 |

(continued to the next page)
300 healthy volunteers. Some important vaccines that are registered for the phase-II clinical trials are mRNA based vaccine (NCT04405076), Ad5 vector (NCT04341389), and DNA vaccine (NCT04445389) (Table 2).

Vaccines that are registered for the phase-III clinical trials are analyzed for the immune response and side effects. In this stage, the vaccine is applied to 1,000 to 3,000 healthy volunteers. Some vital vaccines that are registered for phase-III are mRNA vaccine (NCT04470427) and adsorbed COVID-19 (inactivated) vaccine (NCT04456595) (Table 3).
REPURPOSED VACCINES FOR COVID-19 AND CLINICAL TRIAL

Already approved vaccines that are licensed for various infectious diseases have been shown to enhance the immune system and protect against COVID-19. Bacillus Calmette–Guérin (BCG), polio, and MMR vaccines are being repurposed for COVID-19 (Table 4). Near about 8 controlled trials on repurposed vaccines are currently in progress. It has been observed that the BCG vaccine has been tested in clinical trials for health workers in different countries, such as the Netherlands, Australia, and South Africa (66).

BCG vaccine in the context of COVID-19 pandemic

BCG vaccine is a live attenuated vaccine, and the vaccine strain was derived from Mycobacterium bovis. The vaccine can induce nonspecific immunity. Utilizing nonspecific immunity, the vaccine shows protection against several bacterial and viral pathogens, which is called ‘off-target’ protection. Several scientists are providing the hypothesis that this vaccine may protect against severe COVID-19 (70,71). The BCG vaccines have been tested in clinical trials for health workers in different countries, such as the Netherlands, Australia, and South Africa (66). However, there is no sufficient evidence to recommend the use of BCG for the control of COVID-19.

SOME SIGNIFICANT VACCINE CANDIDATES AND ITS DEVELOPERS

The mRNA-1273 from ModernaTX, Inc

ModernaTX, Inc developed a novel LNP-encapsulated mRNA-based vaccine called mRNA-1273 vaccine. This vaccine encodes the complete stabilized S-protein of SARS-CoV-2. LNPs are constituted of diverse components such as ionizable lipid, 3 commercially available lipids, SM-102, DSPC, PEG2000 DMG, and cholesterol. This vaccine has completed phase-I clinical trial (NCT04283461). The phase-I clinical trial was open-label, and NIH, USA carried...
A dose-ranging trial. Phase-I study helps to understand the immunogenicity and safety of the vaccine. A total of 120 healthy human participants were enrolled in the study. Human subjects received intramuscular (IM) injection in the deltoid muscle with either 10 or 100 μg of mRNA-1273 in 1 ml of 1× PBS into the right hind leg. Orthogonal studies confirmed the role of the mRNA-1273 vaccine in the induction of S-specific CD4 T cells, followed by the production of IL-21, suggesting the generation of potent Ab response (52). Moreover, higher ACE2 binding inhibition and higher neutralizing activity were observed with the mRNA-1273 vaccine candidate (52). The patient can be vaccinated twice after a 28-day interval, which will again have a follow up for 1 year (53,72). Phase-II clinical trial (NCT04405076) for mRNA-1273 was a randomized, placebo controlled, clinical trial. Study evaluated the reactogenicity, immunogenicity and safety of mRNA-1273. In this study, 600 participants (young adults [18–54 years] and olders [65+ years]) were enrolled. In patents 2 doses were analysed (50 mcg and 100 mcg). This vaccine showed 94.5% effectiveness in phase-III trial (NCT04470427). More than 30,000 US participants were enrolled in this trial. Participants even included about 5,000 individuals under 65 years of age with high-risk chronic disease and 7,000 individuals over 65 years of age (73,74).

Ad5 vectored COVID-19 vaccine from CanSino Biologics Inc.
CanSino Biologics is a Chinese biopharmaceutical company that developed the Ebola vaccine (Ad5-EBOV). CanSino Biologics and Beijing Institute of Biotechnology developed Ad5 vectored COVID-19 vaccine (Ad5-nCoV) that is currently in phase-III clinical trial...
(NCT04526990) in collaboration with CDC Jiangsu Province, CDC Hubei Province, Academy of Military Medical Sciences, and Tongji Hospital. It is a recombinant vaccine that was developed from Ad5 vector (75,76). The open-label phase-I clinical trial was completed with 108 healthy volunteers in-between 18 to 60 years of age. The 108 participants were divided into three groups and received single IM injection in a dose-escalating manner (5×10⁹ viral particles per 0·5 ml, 1×10¹¹ viral particles per ml or 1·5×10¹¹ viral particles per 1·5 ml) in the deltoid muscle (77). At 28 days after vaccination, it was observed that the Ad5 vectored COVID-19 vaccine can induced humoral and T cell responses. Moreover, both CD4⁺ and CD8⁺ T cells were activated in vaccine recipients (77). On the other hand, they have also completed the phase-II trial to understand the immunogenicity and safety. In this study, 603 volunteers were recruited. The volunteers received 2 types of doses. Some volunteers received 1×10¹¹ viral particles and other received 5×10¹⁰ viral particle. Although, adverse reactions were reported by 72% from first group and 74% from second group, no serious adverse reactions were observed from the study. Therefore, the study concluded that 5×10¹⁰ viral particles are safe for vaccination (78).

INO-4800 from Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company that developed a DNA based INO-4800 vaccine. This vaccine completed phase-I clinical trial (NCT04336410), in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), and is currently registered in phase-II clinical trial (NCT04447781), to evaluate the tolerability, safety, and immunological profile of this vaccine. This Clinical study has recruited 120 participants who will receive one intradermal injection from 0·5 mg to 1 mg, as per the study group, followed by EP (electroporation) using CELLECTRA® 2000. The vaccine is administered on day 0 and wk 4. Preclinical results showed that mice and guinea pigs vaccinated with INO-4800 showed induction of Ag-specific T cell responses and SARS-CoV-2 neutralizing antibodies. Moreover, inhibition of spike protein binding to the ACE2 receptor and the presence of antibodies against SARS-CoV-2 in the lungs were also observed (47).

LV-SMENP-DC from Shenzhen Geno-Immune Medical Institute

Shenzhen Geno- Immune Medical Institute in collaboration with Third People’s Hospital, Shenzhen and Second People’s Hospital, Shenzhen developed a lentiviral vaccine (LV-SMENP-DC) that is based on the conserved domains of polyprotein protease and the viral structural proteins. They used a lentivirus vector system to modify dendritic cells (DC) and activate T cells by expressing immune-modulatory genes and viral proteins. This vaccine candidate is registered in phase-I/phase-II clinical trial (NCT04276896). This study recruited 100 participants who are receiving 5×10⁶ LV-DC vaccine and 1×10⁸ CTLs via injection (subcutaneous) and intravenous infusion, respectively.

The aAPC vaccine from Shenzhen Geno-Immune Medical Institute

Shenzhen Geno- Immune Medical Institute is developing another vaccine for SARS-CoV-2, which is based on a lentiviral vector system that can modify aAPC and can activate T cells via expressing viral proteins and immune-modulatory genes. This vaccine candidate is registered in phase-I clinical trial (NCT04299724) in collaboration with Shenzhen second people’s hospital and Shenzhen third people’s hospital. This study recruited 100 participants who are receiving a 3 subcutaneous injection with a total of 5×10⁶ cells each time on days 0th, 14th, and 28th.

LUNAR-COV19 from Arcturus Therapeutics

Arcturus Therapeutics has formed a partnership with the Duke-National University of Singapore Medical School to develop an mRNA vaccine against SARS-CoV-2. They are
developing mRNA STARR™ Technology in combination with the LUNAR® RNA medicine delivery technology based LUNAR-COV19 (ARCT-021) vaccine. This is a self-replicating low dose mRNA vaccine that encodes for the prefusion spike protein of SARS-CoV-2. This vaccine can be produced more quickly than a protein-based vaccine, and the duration of Ag expression is more, resulting in prolonged protection from COVID-19 with a single dose. It is registered for phase-I/phase-II clinical trial (NCT04480957), with 92 healthy participants (age between 21 to 55 years). This study is expected to complete in December 2020.

**Adjuvanted protein vaccine from GSK and Sanofi**

GSK and Sanofi S.A. are multinational Biopharmaceutical companies. They are developing the adjuvanted protein vaccine for SARS-CoV-2. Sanofi has provided S protein Ag which is developed through recombinant DNA technology. On the other hand, GSK has provided adjuvant technology for the production of this vaccine. It is in preclinical trial and will enter in phase-I clinical trial (47).

**The mRNA vaccine (BNT162) from BioNTech SE**

BioNTech is Biopharmaceutical Company, which is also called as BioNTech RNA Pharmaceuticals GmbH. In collaboration with Pfizer, BioNTech is developing mRNA vaccine candidate against SARS-CoV-2 which is under clinical trial (79). Two types of clinical trials are registered for this mRNA vaccine in ClinicalTrials.gov. The first one is NCT04380701, which consists of 4 BNT162 vaccines (BNT162a1, BNT162b1, BNT162b2, and BNT162c2). This is a multicentric phase-I/phase-II clinical study with 456 participants. Single to escalating doses of these vaccines are IM injected in different groups of patients. Second study is NCT04368728, which consists of BNT162b1 (phase-II) and BNT162b2 (phase-III) vaccines. In this study 43,998 participants have enrolled who are taking mid dose to low dose of vaccine though IM injection. Recently it was reported that phase-III clinical trial is completed for BNT162b2 and has applied for vaccine licensing in USA (74).

**Synthetic mRNA vaccine from Curevac**

CureVac is a biopharmaceutical company that has developed a synthetic mRNA vaccine for COVID-19. They have completed phase-I clinical trial (NCT04449276) in collaboration with the CEPI. This study recruited 168 participants who are receiving vaccine through IM injection at escalating dose on day 1 and day 29 at the dose levels of 2, 4, and 8 μg. They have also completed phase-II clinical trial (NCT04515147), and initiation of phase-III of clinical trial is in pipeline (74).

**COVAX19 from Vaxine**

Vaxine, a biotechnology company dealing in vaccine development, have developed COVAX19 vaccine against SARS-CoV-2 in collaboration with Central Adelaide Local Health Network Incorporated. It contains SARS-CoV-2 recombinant spike Ag with Advax-5M adjuvant. This vaccine is registered in phase-I clinical trial (NCT04453852) where 40 participants are enrolled. The human volunteer will receive the 25μg vaccine Spike Ag and 15 mg Advax-2 adjuvant.

**AdVac and PER.C6 Technology based vaccine from Johnson & Johnson**

Johnson & Johnson is a pharmaceutical company that has developed adenovirus-vector based vaccine for COVID-19 using 2 technologies, i.e. AdVac® and PER.C6® technology. For this project this company has collaborated with Biomedical Advanced Research and Development Authority. The product is in preclinical trial.
**ChAdOx1 nCoV-19 from University of Oxford**

The University of Oxford (Jenner Institute) along with the Oxford Vaccine Group has developed the ChAdOx1 nCoV-19 vaccine for the pandemic virus. This vaccine showed protectiveness in vaccinated animals against pneumonia (80). This vaccine is registered for the phase-I/phase-II and phase-II/phase-III clinical trial.

We found 2 clinical trial entries for this vaccine in the ClinicalTrials.gov. First one is noted as NCT04324606 which is dealing with phase-I/phase-II as well as randomized clinical study with 1,090 participants volunteers (aged 18–55 years). They have divided the participants into 13 groups (group 1a, group 1b, group 2a, group 2b, group 2c, group 2d, group 2e, group 3, group 4a, group 4b, group 4c, group 4d). Here, the participants received a single variable dose of this vaccine via IM injection with or without paracetamol to determine the immunogenicity and efficacy. Folegatti et al., (81) has published preliminary report of this clinical trial which showed increased and boosting homologus Ab response, as well as suitable safety profile of this vaccine against this pandemic virus.

Second one is noted as NCT04400838 which is dealing with phase-II/phase-III randomized clinical study with 10,260 participants’ volunteers. In this study the participants are divided in 8 different groups (groups 1 & 7 with 56–69 years age; groups 2 & 8 with 70 year of age and over; group 3 with children with 5–12 years of age; groups 4 and 6 with 18 years of age; group 5 with 18–55 years of age). Recently Ramasamy et al. (82) reported the preliminary findings of safety and immunogenicity of ChAdOx1 nCoV-19 from a single-blind, randomised, phase-II/phase-III clinical trial. The study shows that the vaccine is better tolerated in older adults compare to younger adults. After a boost dose, the vaccine has alike immunogenicity throughout all age groups (82). Serum institute of India has collaborated for the production of ChAdOx1 nCoV-19 vaccine (83).

**CHALLENGES INFLUENCING THE DEVELOPMENT OF COVID-19 VACCINE**

There are several other factors which are influencing the vaccine development of COVID-19 (Fig. 1B).

The vaccine development is in itself a long process and takes near about 10 years per vaccine in general (84). However, the hour of need is to develop this vaccine at a pandemic speed. Because of the limited time span, the vaccine clinical trial phases are overlapping in this case to fight against the pandemic (71). The phase-I to phase-III timelines are very extensive, and all the regulatory authority of vaccine licensing are thinking about a new timeline for this vaccine.

Vaccine development process (up to licensing of the vaccine) requires huge money involvement. It has been estimated that the cost of development to bring a vaccine candidate to the end of phase-II trials requires US$31–68 million (85). Collaboration is the most significant strategy for therapeutic development and new research (86). Therefore, a different representative from the academia and biopharmaceutical companies is collaborating to fulfill the growing demands (87). The collaborations between the private and public sector might help to develop this vaccine very quickly.
There is a need for billions dosages of this vaccine and it create high production requirement. Therefore, the proper bio manufacturing infrastructure should be developed in this direction, including the and up to the finish product development.

CONCLUSION

To develop the COVID-19 vaccine, it is critical to understand the interactive modulation of viral proteins with human host receptors. Furthermore, it is essential to understand the mechanism of protective immune responses against SARS-CoV-2 infection. These understandings might facilitate the development of a potential vaccine for COVID-19 by providing us guidance for appropriate Ag selection. Till now, extensive academic and research collaborations have enabled the development of various vaccines for COVID-19 that are currently under clinical trials, mostly in phase-I/phase-II/phase-III. Some vaccine have completed phase-III and have applied for licensing. As the clinical trials and approval of vaccines is a long-term process, we need to do out-of-the-box planning for getting the fast regulatory approval, funding for the vaccine, creation of cGMP production facility, and enhanced bio manufacturing capacity for this vaccine. What we need to understand is that it is global security urgency, and we should move appropriately and promptly towards generating the vaccine against COVID-19.

ACKNOWLEDGEMENTS

This study was supported by Hallym University Research Fund and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1C1C1008694 & NRF-2020R11A3074575).

SUPPLEMENTARY MATERIALS

**Supplementary Table 1**
Different platforms of COVID-19 vaccine development with their advantages and disadvantages. List of various companies or organizations utilizing these platforms

Click here to view

**Supplementary Table 2**
Vaccine in preclinical development stage for COVID-19

Click here to view

REFERENCES

1. Sharpe HR, Gilbride C, Allen E, Belij-Rammerstorfer S, Bissett C, Ewer K, Lambe T. The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. *Immunology* 2020;160:223-232.
2. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. *Eur Rev Med Pharmacol Sci* 2020;24:4016-4026.

3. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. *J Infect* 2020;80:e14-e18.

4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054-1062.

5. Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. *Trends Pharmacol Sci* 2020;41:363-382.

6. Chen W. Promise and challenges in the development of COVID-19 vaccines. *Hum Vaccin Immunother* 2020;16:2604-2608.

7. Lurie N, Saville M, Hatchett R, Halton J. Developing COVID-19 vaccines at pandemic speed. *N Engl J Med* 2020;382:1969-1973.

8. Peeples L. News feature: avoiding pitfalls in the pursuit of a COVID-19 vaccine. *Proc Natl Acad Sci U S A* 2020;117:8218-8221.

9. Heaton PM. The COVID-19 vaccine-development multiverse. *N Engl J Med* 2020;383:1986-1988.

10. Martin JE, Louder MK, Holman LA, Gordon II, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. *Vaccine* 2008;26:6338-6343.

11. Folegatti PM, Bitrye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vector vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. *Lancet Infect Dis* 2020;20:816-826.

12. Fuller DH, Berglund P. Amplifying RNA vaccine development. *N Engl J Med* 2020;382:2469-2471.

13. Yi C, Yi Y, Li J. mRNA vaccines: possible tools to combat SARS-COV-2. *Virol Sin* 2020;35:259-262.

14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.

15. Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. *Curr Top Med Rep* 2020;1:4.

16. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. *Virology* 2020;70:299.

17. Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. *Nat Rev Immunol* 2020;20:347-348.

18. Du L, Zhao G, He Y, Gao Y, Zheng BJ, Jiang S, Zhou Y. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. *Vaccine* 2007;25:2832-2838.

19. De Groot AS, Moise L, McMurry JA, Martin W. Epitope-based immune-derived vaccines: a strategy for improved design and safety. In: Clinical applications of immunomics. Falus A, ed. New York, NY: Springer; 2009. p.39-69.

20. Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, Lee SS, Chakraborty C. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-CoV-2): immunoinformatics approach. *J Med Virol* 2020;92:618-631.
21. Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, Saha RP, Lee SS, Chakraborty C. A SARS-CoV-2 vaccine candidate: in-silico cloning and validation. Inform Med Unlocked 2020;20:100394.

22. Giurgea LT, Han A, Memoli MJ. Universal coronavirus vaccines: the time to start is now. NPJ Vaccines 2020;5:43.

23. Yuan M, Wu NC, Zhu X, Lee CD, So RT, Lv H, Mok CK, Wilson IA. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020;368:630-633.

24. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020;9:382-385.

25. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-1263.

26. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215-220.

27. Wang C, Li W, Drabek D, Okba NM, van Haperen R, Osterhaus AD, van Kuppeveld FJ, Haagmans BL, Grosveld F, Bosch BJ. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020;11:1-6.

28. Ella KM, Mohan VK. Coronavirus vaccine: light at the end of the tunnel. Indian Pediatr 2020;57:407-410.

29. Melgaço JG, Azamor T, Ano Bom AP. Protective immunity after COVID-19 has been questioned: what can we do without SARS-CoV-2-IgG detection? Cell Immunol 2020;353:104114.

30. Priyanka , Choudhary OP, Singh I. Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components. Travel Med Infect Dis 2020;39:101911.

31. Casanova JL, Su HCCOVID Human Genetic Effort. A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell 2020;181:1194-1199.

32. Manners C, Larios Bautista E, Sidoti H, Lopez OJ. Protective adaptive immunity against severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) and implications for vaccines. Curesus 2020;12:e8399.

33. Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020;586:572-577.

34. Bakker WA, Thomassen YE, van’t Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van’t Veld P, Sleeman E, van Nimwegen FW, Hamidi A, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011;29:7188-7196.

35. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020;369:77-81.

36. Risson E. Inactivated vaccine for SARS-CoV-2. Nat Rev Immunol 2020;20:353.

37. Lazar M, Stănescu A, Penedos AR, Pistol A. Characterisation of measles after the introduction of the combined measles-mumps-rubella (MMR) vaccine in 2004 with focus on the laboratory data, 2016 to 2019 outbreak, Romania. Euro Surveill 2019;24:1900041.

38. Grenga L, Gallais F, Pible O, Gaillard JC, Gouveia D, Batina H, Bazaïne N, Ruat S, Culotta K, Miotello G, et al. Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines. Emerg Microbes Infect 2020;9:1712-1721.

39. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, Hotz P. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 2012;11:1405-1413.
40. Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. *ChemMedChem* 2013;8:360-376.

41. Flood A, Estrada M, McAdams D, Ji Y, Chen D. Development of a freeze-dried, heat-stable influenza subunit vaccine formulation. *PLoS One* 2016;11:e0164692.

42. Kalita P, Padhi AK, Zhang K-YI, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. *Microb Pathog* 2020;145:104236.

43. Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. *NPJ Vaccines* 2020;5:18.

44. Qi X, Ke B, Feng Q, Yang D, Lian Q, Li Z, Lu L, Ke C, Liu Z, Liao G. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. *Chem Commun (Camb)* 2020;56:8683-8686.

45. Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. *Expert Opin Drug Deliv* 2014;11:885-899.

46. Saha RP, Sharma AR, Singh MK, Samanta S, Bhakta S, Mandal S, Bhattacharya M, Lee SS, Chakraborty C. Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against COVID-19. *Front Pharmacol* 2020;11:1258.

47. Smith TR, Patel A, Ramos S, Elwood D, Zhu X, Yan J, Gary EN, Walker SN, Schultheis K, Purwar M, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. *Nat Commun* 2020;11:2601.

48. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nikolola IP, Liu J, Li Z, Chandrashekar A, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* 2020;369:806-811.

49. Walker SN, Chokkalingam N, Reuschel EL, Purwar M, Xu Z, Gary EN, Kim KY, Helble M, Schultheis K, Walters J, et al. SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients. *J Clin Microbiol* 2020;58:e01533-20.

50. Kaur SP, Gupta V. COVID-19 Vaccine: a comprehensive status report. *Virus Res* 2020;288:198114.

51. Amanat F, Krammer F. SARS-CoV-2 vaccines: Status report. *Immunity* 2020;52:S83-S89.

52. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *N Engl J Med* 2020;383:1544-1555.

53. Anderson EL, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruissers AJ, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *N Engl J Med* 2020;383:2427-2438.

54. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, et al. Phase II/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 2020;586:589-593.

55. Krammer F. SARS-CoV-2 vaccines in development. *Nature* 2020;586:516-527.

56. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *N Engl J Med* 2020;383:1544-1555.

57. Koch T, Dahleke C, Fathi A, Kupke A, Krähling V, Okba NM, Halwe S, Rohde C, Eickmann M, Volz A, et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. *Lancet Infect Dis* 2020;20:827-838.
58. Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, Raj VS, Epperly MW, Klimstra WB, Haagmans BL, et al. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. *EbioMedicine* 2020;55:102743. 
PUBMED | CROSSREF

59. Deangelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, et al. Clinical trial registration: a statement from the international committee of medical journal editors. *Arch Dermatol* 2005;141:76-77. 
PUBMED | CROSSREF

60. Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. *Braz J Med Biol Res* 2012;45:1102-1111. 
PUBMED | CROSSREF

61. Funk CD, Laferrière C, Ardakani A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. *Front Pharmacol* 2020;11:937. 
PUBMED | CROSSREF

62. Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. *Vaccines (Basel)* 2014;2:515-536. 
PUBMED | CROSSREF

63. Gregusic EV, Anderson DA. Virus-like particles: passport to immune recognition. *Methods* 2006;40:60-65. 
PUBMED | CROSSREF

64. Roltovie MJ, Nagasawa M, Swartz JR. Virus-like particles: next-generation nanoparticles for targeted therapeutic delivery. *Bioeng Transl Med* 2017;2:43-57. 
PUBMED | CROSSREF

65. Mullard A. COVID-19 vaccine development pipeline gears up. *Lancet* 2020;395:1751-1752. 
PUBMED | CROSSREF

66. Saeidnia S, Manayi A, Abdollahi M. From *in vitro* experiments to *in vivo* and clinical studies; pros and cons. *Curr Drug Discov Technol* 2015;12:218-224. 
PUBMED | CROSSREF

67. Raimondi MT, Donnaloja F, Barzaghi F, Bocconi A, Conci C, Parodi V, Jacchetti E, Carelli S. Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19. *Theranostics* 2020;10:7034-7052. 
PUBMED | CROSSREF

68. Cohen J. Vaccine designers take first shots at COVID-19. *Science* 2020;368:14-16. 
PUBMED | CROSSREF

69. Kim YC, Dema B, Reyes-Sandoval A. COVID-19 vaccines: breaking record times to first-in-human trials. *NPJ Vaccines* 2020;5:34. 
PUBMED | CROSSREF

70. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). *Proc Natl Acad Sci U S A* 2020;117:17720-17726. 
PUBMED | CROSSREF

71. Mohapatra PR, Mishra B, Behera B. BCG vaccination induced protection from COVID-19. *Indian J Tuberc* 2020. doi: 10.1016/j.ijtb.2020.08.004. 
CROSSREF

72. Banday AH, Shameem SA, Ajaz SJ. Potential repurposed therapeutics and new vaccines against COVID-19 and their clinical status. *SLAS Discov* 2020;25:1097-1107. 
PUBMED | CROSSREF

73. Mahase E. COVID-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. *BMJ* 2020;371:m4471. 
CROSSREF

74. Dolgin E. COVID-19 vaccines poised for launch, but impact on pandemic unclear. *Nat Biotechnol* 2020. doi: 10.1038/d41587-020-00022-y. 
PUBMED | CROSSREF

75. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov* 2020;19:305-306. 
PUBMED | CROSSREF

76. Bar-Zeev N, Moss WJ. Encouraging results from phase 1/2 COVID-19 vaccine trials. *Lancet* 2020;396:448-449. 
PUBMED | CROSSREF

77. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet* 2020;395:1845-1854. 
PUBMED | CROSSREF
78. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396:479-488.

79. Martin C, Lowery D. mRNA vaccines: intellectual property landscape. Nat Rev Drug Discov 2020;19:578.

80. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham IN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 2020;586:578-582.

81. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-478.

82. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised controlled phase 2/3 trial. Lancet 2020;6736:32466-1.

83. Chakraborty C, Agoramoorthy G. India’s cost-effective COVID-19 vaccine development initiatives. Vaccine 2020;38:7883-7884.

84. Bregu M, Draper SJ, Hill AV, Greenwood BM. Accelerating vaccine development and deployment: report of a Royal Society satellite meeting. Philos Trans R Soc Lond B Biol Sci 2011;366:2841-2849.

85. Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health 2018;6:e1386-e1396.

86. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Saha RP, Lee SS. Extensive partnership, collaboration, and teamwork is required to stop the COVID-19 outbreak. Arch Med Res 2020;51:728-730.

87. Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science 2020;368:948-950.